Financial Architects (New Jersey)’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Financial Architects (New Jersey)’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-64	Closed	-$2K	–	1715
2017 Q1	$2K	Hold	64	–	–	﹤0.01%	1495
2016 Q4	$2K	Hold	64	–	–	﹤0.01%	1324
2016 Q3	$3K	Hold	64	–	–	﹤0.01%	1296
2016 Q2	$3K	Hold	64	–	–	﹤0.01%	1266
2016 Q1	$4K	Buy	+64	New	+$3.34K	﹤0.01%	956
2015 Q3	–	Sell	-64	Closed	-$6K	–	1116
2015 Q2	$6K	Hold	64	–	–	﹤0.01%	932
2015 Q1	$6K	Hold	64	–	–	﹤0.01%	859
2014 Q4	$6K	Hold	64	–	–	﹤0.01%	815
2014 Q3	$4K	Hold	64	–	–	﹤0.01%	790
2014 Q2	$4K	Buy	+64	New	+$3.25K	﹤0.01%	821

Other funds holding MACK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Financial Architects (New Jersey)'s MACK Position: Q2 2017 in Review

Financial Architects (New Jersey) sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2017, closing a stake of 64 shares — an estimated $2K sold.

Financial Architects (New Jersey) first reported a position in MACK in Q2 2014 and held it in 10 quarters. The position peaked at $6K in Q2 2015. 119 funds tracked by Wall St. Rank hold MACK as of Q2 2017.

Financial Architects (New Jersey) reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
Financial Architects (New Jersey) sold 64 Merrimack Pharmaceuticals, Inc. shares in Q2 2017, an estimated $2K.
Financial Architects (New Jersey) first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2014 and held it in 10 quarters.
Financial Architects (New Jersey)'s Merrimack Pharmaceuticals, Inc. position peaked at $6K in Q2 2015.
119 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2017.

Based on Financial Architects (New Jersey)'s 13F filing for Q2 2017, filed 21 Jul 2017.